Kura Oncology, Inc. financial data

Symbol
KURA on Nasdaq
Location
12730 High Bluff Drive, Suite 400, San Diego, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 4, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 693 % -49.4%
Debt-to-equity 114 % +897%
Return On Equity -65.4 % -48.4%
Return On Assets -30.6 % +22.7%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 87M shares +11.9%
Common Stock, Shares, Outstanding 87M shares +11.9%
Entity Public Float 1.6B USD +106%
Common Stock, Value, Issued 9K USD +12.5%
Weighted Average Number of Shares Outstanding, Basic 87.6M shares +0.8%
Weighted Average Number of Shares Outstanding, Diluted 87.6M shares +0.8%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 20.8M USD
Research and Development Expense 239M USD +59%
General and Administrative Expense 105M USD +56%
Nonoperating Income (Expense) 25.2M USD +26.2%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -215M USD -36.2%
Income Tax Expense (Benefit) 226K USD
Net Income (Loss) Attributable to Parent -217M USD -9.79%
Earnings Per Share, Basic -2 USD/shares -4.66%
Earnings Per Share, Diluted -2 USD/shares -4.66%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 95.3M USD +92.6%
Accounts Receivable, after Allowance for Credit Loss, Current 35.9M USD
Assets, Current 621M USD +34%
Property, Plant and Equipment, Net 7.4M USD +463%
Operating Lease, Right-of-Use Asset 7.54M USD +23.6%
Other Assets, Noncurrent 13.8M USD +67.4%
Assets 649M USD +35.6%
Accounts Payable, Current 4.67M USD +55.4%
Employee-related Liabilities, Current 14.6M USD +16.9%
Contract with Customer, Liability, Current 48.8M USD
Liabilities, Current 121M USD +200%
Contract with Customer, Liability, Noncurrent 269M USD
Operating Lease, Liability, Noncurrent 8.36M USD +53%
Other Liabilities, Noncurrent 2.98M USD +103%
Liabilities 407M USD +639%
Accumulated Other Comprehensive Income (Loss), Net of Tax 711K USD
Retained Earnings (Accumulated Deficit) -1.09B USD -24.8%
Stockholders' Equity Attributable to Parent 243M USD -42.8%
Liabilities and Equity 649M USD +35.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -71.9M USD -47.3%
Net Cash Provided by (Used in) Financing Activities 143K USD
Net Cash Provided by (Used in) Investing Activities -101M USD -6.37%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 87M shares +11.9%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -173M USD -4235%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 95.3M USD +92.6%
Deferred Tax Assets, Valuation Allowance 279M USD +24.4%
Deferred Tax Assets, Gross 281M USD +23.9%
Operating Lease, Liability 9.79M USD +36.8%
Depreciation 241K USD +2.99%
Payments to Acquire Property, Plant, and Equipment 292K USD +248%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -217M USD -12.5%
Lessee, Operating Lease, Liability, to be Paid 24.5M USD +142%
Property, Plant and Equipment, Gross 11.3M USD +157%
Operating Lease, Liability, Current 1.43M USD -15.5%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.53M USD +14.1%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.53M USD -21.9%
Operating Lease, Weighted Average Discount Rate, Percent 0.12 pure +8.93%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 8.84M USD +201%
Lessee, Operating Lease, Liability, to be Paid, Year Three 3.66M USD +167%
Deferred Tax Assets, Operating Loss Carryforwards 97.6M USD -32.4%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 15.4M USD +52.7%
Lessee, Operating Lease, Liability, to be Paid, Year Four 3.75M USD +169%
Operating Lease, Payments 1.5M USD +66.7%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 11M USD +31.7%
Interest Expense 1.6M USD +4.91%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%